I RECENTLY spoke at the 53rd Artdo International Conference in Kota Kinabalu, Sabah, expecting to talk about human capital in an age of artificial intelligence (AI), agility and authenticity. I did.
But somewhere between AI and the future of people, the conversation became considerably smaller: tocotrienols, the lesser-known members of the vitamin E family.
From algorithms to antioxidants – not quite the conference detour I had expected.
At the conference, I met academician Tan Sri Emeritus Prof Datuk Dr Augustine S.H. Ong, Emeritus Prof Dr Yuen Kah Hay, a leading Malaysian pharmacist and palm-tocotrienol researcher, and his former top PhD student Dr Sherlyn Lim Sheau Chin.
Our conversation wandered, as good conversations often do, from research to palm oil and eventually vitamin E.
I told them I wanted to write about tocotrienols in a way ordinary people could understand. This is it.
If I were palm oil, I might complain that people know my controversies better than my chemistry.
Mention me at dinner and somebody will eventually bring up saturated fat, orangutans, deforestation, smallholders, the European Union or why I have sneaked into biscuits.
I have been criticised, defended, certified, boycotted, traced and regulated. Yet, very few people have looked me quietly in the molecule.
If they did, they might discover something interesting inside the reddish- orange fruit of the oil palm: vitamin E.
More precisely, a lesser-known branch of the vitamin E family called tocotrienols.
Do not worry if the word is unfamiliar. Tocotrienol sounds less like a nutrient than something a mechanic might recommend when the tractor develops an expensive noise. Yet, it may be one of palm oil’s most interesting passengers.
And therein lies a bigger Malaysian story. We have spent generations counting hectares, tonnes of fresh fruit bunches, oil extraction rates and export volumes.
Tocotrienols invite us to look in the opposite direction – towards compounds measured in milligrams. Sometimes the smallest things inside a commodity may point towards its largest opportunities.
Vitamin E has two sides to the family
Most of us grew up thinking vitamin E was one thing. Chemistry, as usual, complicates a perfectly serviceable story.
Vitamin E is actually a family with two branches: tocopherols and tocotrienols. Each branch has four members – alpha, beta, gamma and delta – giving eight naturally occurring forms.
They are close cousins, and both help protect the fats and membranes of our cells from oxidative damage while also influencing inflammation, immune responses and cell signalling.
They are not identical workers wearing the same uniform.
Alpha-tocopherol is the best-known because our bodies retain it particularly well: the liver strongly favours it, keeping it in circulation and tissues.
That is why it became almost synonymous with vitamin E and remains the form used to define our nutritional requirement.
Tocotrienols are the less famous cousins.
They look chemically similar, but their molecular tail contains three double bonds.
That small structural difference appears to affect how they move within fatty cell membranes and interact with biological systems.
For the non-scientist, think of alpha- tocopherol as the reliable housekeeper.
Our bodies know it well and retain it efficiently. Tocotrienol is the more adventurous cousin – turning up in more rooms and making scientists ask what else it might do.
Same family. Different job descriptions
For much of the past century, alpha- tocopherol dominated the vitamin E family photograph.
A major scientific review published in 2006 noted that fewer than 1% of vitamin E papers indexed in PubMed dealt with tocotrienols.
The quieter cousins had barely been invited into the laboratory.
That has changed considerably as scientists recognise that putting all eight forms under one convenient “vitamin E” label can hide important differences.
Oil palm, meanwhile, had been carrying tocotrienols all along.
Tocotrienols also occur in rice bran, barley, wheat and oats, but palm oil stands out because its vitamin E is naturally dominated by tocotrienols – typically around 70% to 80%.
Put simply, if palm oil’s vitamin E family occupied ten chairs, seven or eight would belong to tocotrienols.
Professor Yuen helped me put those milligrams into perspective. Crude palm oil may contain around 700mg to 800mg of tocotrienols per kilogram, depending on fruit quality.
If a 20 gramme fruitlet yields roughly three gramme of oil, the tocotrienols in about 50 fruitlets could theoretically provide 100mg in a capsule.
Suddenly the chemistry becomes visible: from fruit bunch to mill, from oil to molecule, from tonnes to milligrams.
Same jacket, different trousers
Why should tocotrienols behave differently from tocopherols if both belong to vitamin E?
Part of the answer lies in their shape. Both share essentially the same antioxidant “head”, but tocopherols have a saturated molecular tail while tocotrienols carry three double bonds.
Hence the “tri”. If molecules wore clothes, tocopherol and tocotrienol could arrive at the same family reunion wearing similar jackets but noticeably different trousers. And those trousers may matter.
The unsaturated tail appears to give tocotrienols greater mobility within fatty cell membranes, helping them spread and interact effectively with damaging molecules created during oxidation. This may explain why some laboratory experiments have found tocotrienols stronger antioxidants than tocopherols under particular conditions.
The useful message is not that tocotrienol is simply a stronger tocopherol, but that tocotrienols behave differently. Their scientific interest also extends beyond antioxidant activity.
Researchers have investigated tocotrienols in relation to inflammation, cell signalling, cholesterol production and nerve-cell survival. A difference that looks tiny on a chemistry diagram can translate into a different biological personality.
From laboratory promise to human evidence
So what might tocotrienols actually do for people? Quite a lot has attracted scientific attention.
Researchers have explored their antioxidant and anti-inflammatory activity, cardiovascular and metabolic health, nerve protection, brain health and cell signalling.
Laboratory studies have also identified effects on pathways involved in the body’s own cholesterol production and nerve-cell survival.
More importantly, the story has moved beyond the test tube.
A 2024 systematic review examined 30 randomised controlled trials involving more than 2,600 people, from healthy volunteers to participants with diabetes, metabolic conditions and cardiovascular risk.
Tocotrienols are no longer merely interesting molecules waiting for human research; a meaningful body of clinical evidence is taking shape.
Several trials reported favourable changes in indicators of oxidative stress.
In ordinary language, researchers were looking for signs of cellular wear and tear when damaging chemical reactions exceed the body’s protective systems. Some of those signs improved.
That matters because oxidative stress and chronic inflammation are involved in many processes associated with ageing and non-communicable diseases.
A laboratory marker does not prove a disease has been prevented, but it tells us something useful: tocotrienols can produce measurable positive biological effects inside real people, not merely behave impressively in a laboratory dish.
The neurological work is especially interesting. Tocotrienols have been studied in relation to nerve function and changes in the brain’s white matter.
Studies involving people with diabetes have also reported improvements in some measurements of nerve conduction and kidney function.
As Prof Yuen shared with me, the brain may be one of the most promising frontiers for tocotrienol research.
Studies ranging from cultured cells to mice, rats, dogs and early human trials have reported neuroprotective effects - in simple terms, tocotrienols appear able to help protect brain and nerve cells from damage.
That opens an intriguing avenue for research into neurodegenerative diseases.
The evidence is still developing, but the direction is encouraging: there is clearly much more to pursue, and much to look forward to.
Not every measurement improves in every trial, but that is normal science. What is emerging is not one magical molecule doing one magical thing, but a compound that may influence several biological pathways at once.
Researchers are studying antioxidant, anti-inflammatory and cell-signalling effects across different tissues and conditions.
Cholesterol provides another example. Laboratory research has shown that tocotrienols can influence pathways involved in cholesterol production, and some human studies have reported favourable changes in blood lipids.
Results are not identical across every trial, but that does not close the question. It tells scientists where better studies are needed.
Science rarely arrives with a marching band and one final answer; more often, it advances by accumulating clues until the picture or jigsaw puzzle becomes harder to ignore.
There is another intriguing challenge. Once vitamin E enters our bodies, the liver strongly favours alpha-tocopherol, while tocotrienols are generally metabolised and cleared more quickly.
At first sight that looks like a disadvantage. To pharmaceutical scientists, it sounds more like a research question: can we deliver it better?
Researchers are examining formulations designed to improve absorption and bioavailability- how much of what we consume becomes available for the body to use.
Different combinations of alpha-, gamma- and delta-tocotrienols, improved delivery systems and suitable food formulations may help capture more of their potential. So, a biological limitation becomes an innovation opportunity.
Palm oil may contain plenty of tocotrienols, but those molecules still have to survive processing, cross the intestine, enter the bloodstream and reach the tissues where they may act.
The journey from fruit to cell is considerably longer than the journey from bottle to mouth.
Tocopherol has the history. Tocotrienol has the horizon
This is where my Kota Kinabalu conversation brought me back to something larger than vitamin E.
Malaysia already has the plantations, mills, refineries, research institutions, universities, laboratories and downstream manufacturers surrounding oil palm.
We are not searching for a rare compound hidden in an obscure plant.
The supply chain already exists. Palm fruit is harvested and oil produced every day, and palm oil naturally contains a high proportion of its vitamin E as tocotrienols.
That gives Malaysia an unusual combination of natural abundance, commercial availability, scientific capability and industrial scale.
A commodity producer sees a tonne of oil. A chemist sees the compounds within it. An innovator asks how those molecules might become specialised ingredients, better formulations, intellectual property and higher-value products. Same tonne. Different imagination.
For generations, palm oil economics has revolved around hectares, tonnes, extraction rates and commodity prices.
Tocotrienols introduce another vocabulary: milligrams, molecules, clinical trials, formulations, patents and specialised nutrition.
The first generation asks: How much can we grow? The next: How efficiently can we process it? A more sophisticated one asks: What valuable molecules are already inside it, and what knowledge can we build around them?
Alpha-tocopherol deserves its established place. Our bodies preferentially retain it, and its nutritional role is well understood. But tocotrienols may represent the more exciting scientific frontier. Put simply, tocopherol has the longer résumé; tocotrienol has the more intriguing research agenda.
One has been studied for almost a century. The other spent decades largely overlooked, yet research is already producing measurably positive signals in many biological pathways.
The evidence is not complete, but neither is it merely speculative.
Larger, better-designed and more internationally replicated clinical trials should now be pursued to determine how much of that promise can translate into meaningful human benefit.
The science has come far enough to justify taking it further.
For Malaysia, that creates a compelling opportunity.
We possess the crop, processing infrastructure, scientific experience and one of nature’s important commercially available sources of tocotrienols.
What I enjoyed most was the contrast: at a conference in Kota Kinabalu on AI, agility and authenticity, we were discussing something nature had placed inside an oil-palm fruit long before AI arrived.
AI may help us discover faster, agility turn discoveries into applications, and authenticity remind us to understand what we already possess and tell the story truthfully.
The question is no longer whether tocotrienols are interesting, but how far Malaysia can take them.
If I were palm oil, I would be proud of my tocotrienols – not as a miracle, but as science worth pursuing further.
Malaysia has long mastered growing, milling and refining palm oil.
The next frontier may lie deeper inside: turning molecules into knowledge, innovation and value.
The first harvest was fruit. The second was oil. The next may be knowledge and beyond.
Joseph Tek Choon Yee has over 30 years of experience in the plantation industry, with a strong background in oil palm research and development, C-suite leadership and industry advocacy. The views expressed here are the writer’s own.
